A Clearer Strategy for Responding to the Ebola Bundibugyo Outbreak Is Needed

The ongoing Ebola virus disease outbreak caused by Orthoebolavirus bundibugyoense (BDBV) in the Democratic Republic of the Congo highlights persistent gaps in global outbreak preparedness. Despite decades of experience with Ebola, delayed detection, limited access to care, insecurity, community mistrust, and fragmented response systems continue to hinder effective control and reduce survival. While non-pharmaceutical interventions remain essential, potentially effective medical countermeasures should be considered earlier. Existing vaccines and therapeutics developed against Ebola Zaire, although not licensed for BDBV, could be evaluated through carefully governed investigational or compassionate use alongside rigorous research. Effective response also requires strengthened surveillance, decentralized care, community engagement, and meaningful leadership by local scientists and healthcare professionals. This outbreak underscores the need for an adaptive, locally led, and internationally supported strategy that simultaneously saves lives and generates evidence.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-11-09
DOI
https://doi.org/10.3390/vaccines14110965
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Clearer Strategy for Responding to the Ebola Bundibugyo Outbreak Is Needed

Antoine Flahault, Pierre MʼPelé
Vaccines
Viral Infections and Outbreaks Research
article

A Clearer Strategy for Responding to the Ebola Bundibugyo Outbreak Is Needed

Antoine Flahault, Pierre MʼPelé
article en

Abstract

The ongoing Ebola virus disease outbreak caused by Orthoebolavirus bundibugyoense (BDBV) in the Democratic Republic of the Congo highlights persistent gaps in global outbreak preparedness. Despite decades of experience with Ebola, delayed detection, limited access to care, insecurity, community mistrust, and fragmented response systems continue to hinder effective control and reduce survival. While non-pharmaceutical interventions remain essential, potentially effective medical countermeasures should be considered earlier. Existing vaccines and therapeutics developed against Ebola Zaire, although not licensed for BDBV, could be evaluated through carefully governed investigational or compassionate use alongside rigorous research. Effective response also requires strengthened surveillance, decentralized care, community engagement, and meaningful leadership by local scientists and healthcare professionals. This outbreak underscores the need for an adaptive, locally led, and internationally supported strategy that simultaneously saves lives and generates evidence.

VaccinesVol. 14(11)
University of Geneva (CH), Inserm (FR), Université Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Bichat-Claude-Bernard (FR)
Viral Infections and Outbreaks Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon